Comprehensive Community-Acquired Pneumonia Management
- In ICU
- Tue, 21 Oct 2025
Community-acquired pneumonia (CAP) represents a major global health challenge and remains a leading cause of morbidity and mortality worldwide. With an estimated global incidence of 4,350 per 100,000 population in 2021, CAP disproportionately affects vulnerable populations, including older adults, young children, immunocompromised individuals, and those with chronic comorbidities. The disease burden is particularly severe in lower-middle-income countries, where approximately 2.2 million deaths occur annually, translating to 27.7 deaths per 100,000 people. These disparities are exacerbated by limited healthcare access, poor air quality, and inadequate vaccination coverage in resource-constrained settings.
The clinical management of CAP faces numerous challenges, beginning with the absence of a gold standard for rapid and accurate diagnosis of bacterial pneumonia. This diagnostic uncertainty often leads to overuse of empirical antimicrobial therapies, contributing to rising antibiotic resistance, adverse clinical outcomes, and difficulties in patient follow-up. The disease presents with marked variability in respiratory and systemic manifestations between patients, with symptom severity largely dependent on the intensity of the host immune response. Classic symptoms include cough (often productive), dyspnoea, and pleuritic chest pain, accompanied by physical examination findings such as tachypnoea and adventitious breath sounds. However, older or immunocompromised patients may present atypically, without fever or with non-specific findings like confusion or functional decline.
Diagnostic approaches involve identifying pulmonary clinical signs alongside systemic features, including abnormal body temperature, tachypnoea, and tachycardia. While biomarkers such as C-reactive protein and procalcitonin have been investigated, their diagnostic performance is insufficient to guide antimicrobial initiation. However, these biomarkers have proven valuable for antimicrobial de-escalation, with studies showing reduced antibiotic duration from seven days to four to five and a half days when guided by these markers. Radiological assessment through chest radiography, CT imaging, or lung ultrasound remains essential for demonstrating alveolar infiltration and securing diagnosis, with lung ultrasound showing superior sensitivity and specificity compared to plain radiography.
Recent advances in molecular diagnostics, particularly nucleic acid amplification tests (NAATs), are transforming pathogen identification in CAP. These tests enable rapid and accurate detection of bacterial and viral pathogens, including co-infections, with results available within 30 to 120 minutes, depending on the platform. The widespread adoption of molecular testing during the COVID-19 pandemic has accelerated the incorporation of these technologies into clinical practice. Despite extensive diagnostic testing, a specific pathogen can only be identified in less than half of CAP patients, underscoring significant knowledge gaps. Streptococcus pneumoniae remains the most frequently detected bacterial pathogen worldwide, though its incidence has declined in regions with widespread pneumococcal vaccination. Respiratory viruses are now detectable in up to 30% of cases due to advances in molecular diagnostics, with rhinovirus and influenza A and B accounting for a substantial proportion.
The pathophysiology of CAP involves pathogens proliferating rapidly in the lower respiratory tract, provoking robust local and systemic inflammation and subsequent tissue destruction. Essentially all bacterial CAP arises via aspiration of pharyngeal secretions, with disease occurring when a sufficient burden of pathogenic microbes exceeds the host's clearance mechanisms. The inflammatory response triggers recruitment of neutrophils and inflammatory monocytes, whose lytic enzymes and oxidants damage the alveolar epithelium, leading to plasma protein fluid leakage and disruption of gas exchange. These pathological features drive the clinical picture of breathlessness, fever, and progressive hypoxia.
Treatment approaches have evolved towards personalised strategies adapted to clinical severity, demographics, comorbidities, and pathogen detection. Initial therapy is typically empirical, with beta-lactam antibiotics covering typical pathogens and macrolides or fluoroquinolones added for intracellular organisms and severe cases. The optimal duration of antimicrobial treatment ranges from three to five days for outpatients to seven to ten days for ICU patients, guided by clinical stability and biomarker trends. Current guidelines emphasise avoiding prolonged antimicrobial courses except for specific indications such as bacteraemia or complications like empyaema.
The role of adjunctive therapies, particularly corticosteroids, remains an area of active investigation and controversy. While some studies suggest corticosteroids may reduce mortality and decrease the need for mechanical ventilation in severe CAP, particularly in patients with high C-reactive protein levels, the evidence remains inconsistent. The 2025 American Thoracic Society guidelines suggest corticosteroids for severe CAP except in influenza pneumonia, where observational data suggest potential harm. Other immunomodulatory approaches, including targeted therapies used successfully in COVID-19, are being investigated for severe bacterial CAP, though no established immune modulation therapies currently exist outside of clinical trials.
An increasingly recognised aspect of CAP is its long-term complications, challenging the conventional characterisation of pneumonia as solely an acute infection. Growing evidence links CAP to cardiovascular events, persistent respiratory dysfunction, and cognitive decline, particularly among older adults and those with severe disease. Consequently, comprehensive CAP management must extend beyond the acute phase to include long-term follow-up, rehabilitation, routine cardiovascular screening, and prevention strategies. Respiratory complications, including bronchiectasis and COPD exacerbations, are common, while the elevated risk of myocardial infarction, arrhythmias, heart failure, and stroke in the weeks to months after hospitalisation necessitates regular cardiovascular monitoring.
Several important research questions remain unanswered, including the development of new antibiotics to address resistance, optimal protocols for safely discontinuing antibiotics in viral CAP, standardisation of biomarker-guided antimicrobial therapy, and the role of immune phenotyping in personalising treatment. Understanding socioeconomic and environmental influences on CAP risk, the role of the host microbiome in susceptibility, and mechanisms of neurological complications after severe disease represent additional priorities.
The field is moving toward precision medicine approaches that integrate advanced diagnostics with tailored therapies to improve outcomes and reduce the global burden of this pervasive disease. By emphasising early rehabilitation, ongoing screening for complications, and holistic patient management, clinicians can better mitigate CAP's long-term effects and enhance overall survival and quality of life.
Source: The Lancet
Image Credit: iStock
References:
Reyes LF et al. (2025) Community-acquired pneumonia. The Lancet.
